ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 5

Interferon Kappa Promotes the Development of Psoriasis

Mehrnaz Gharaee-Kermani1, Shannon Estadt 1, Sonya Wolf-Fortune 1, Johann Gudjonsson 1 and J. Michelle Kahlenberg 1, 1University of Michigan, Ann Arbor, MI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interferon, psoriasis and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is a one of the most common chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. It affects about 3% of the world’s population, with unknown etiology. In psoriasis, a complex network of cytokines and chemokines is produced by various types of immune cells, but keratinocytes also play a key role in pathogenesis. Early infiltration of plasmacytoid dendritic cells and detection of an interferon (IFN) signature occurs in many psoriasis lesions.  In addition, deletion of the type I IFN receptor is protective in imiquimod-induced psoriasis.  Recently, we described keratinocyte production of IFN-κ as an important source of type I IFN production in the epidermis.  We thus wanted to explore the role of IFN-κ in psoriasis. 

Methods: We used the well-characterized imiquimod (IMQ) psoriasis model for these studies. 10-week old male and female wild type (WT) and mice transgenic for IFN-κ under the K14 promoter (resulting in only epidermal overexpression) were used (n=5-8 per group).  Psoriasis was induced by topical application of IMQ on both ears for 8 consecutive days.  Control mice received Vaseline. Animals were monitored daily for ear thickness, lesion severity, and body weight. On day nine, mice were euthanized and disease severity was compared between WT and IFN-κ transgenic mice. Skin inflammation was assessed via H&E staining.

Results: Although both IFN-κ transgenic and WT IMQ treated mice exhibited psoriasis lesions in both ears after 8 days of treatment, the lesion size and thickness was significantly increased in IFN-κ transgenic mice vs. WT for both male and female mice. Interestingly, the difference was more exaggerated in IFN-κ transgenic female mice vs. male mice.  H&E staining revealed increased inflammatory cell infiltrates in IMQ treated IFN-κ-TG vs. WT mice. Control mice did not show any sign of inflammation or disease. Ongoing studies are characterizing the differences in cell populations that make up the inflammatory infiltrates in WT vs. IFN-κ transgenic mice.

Conclusion: Overexpression of IFN- κ in the epidermis caused accelerated and increased disease severity after topical application of IMQ. This suggests that overproduction of type I IFNs may impact psoriasis development and there may be a role of targeting IFNs in early disease. Further studies will need to elucidate the specific mechanisms that may be at play.


Disclosure: M. Gharaee-Kermani, None; S. Estadt, None; S. Wolf-Fortune, None; J. Gudjonsson, AbbVie, 2, Genentech, 2, genentech, 2, MiRagen, 5, Novartis, 5, Sun Pharma, 2, SunPharma, 2; J. Kahlenberg, AstraZeneca, 5, Eli Lilly, 5, Bristol Myers Squibb, 5.

To cite this abstract in AMA style:

Gharaee-Kermani M, Estadt S, Wolf-Fortune S, Gudjonsson J, Kahlenberg J. Interferon Kappa Promotes the Development of Psoriasis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/interferon-kappa-promotes-the-development-of-psoriasis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-kappa-promotes-the-development-of-psoriasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology